Sanofi (NASDAQ:SNY) Shares Acquired by Jennison Associates LLC

Jennison Associates LLC grew its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 938.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,904,445 shares of the company's stock after purchasing an additional 1,720,972 shares during the quarter. Jennison Associates LLC owned approximately 0.08% of Sanofi worth $109,753,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. POM Investment Strategies LLC purchased a new position in Sanofi during the second quarter worth approximately $25,000. Northwest Investment Counselors LLC purchased a new position in shares of Sanofi during the 3rd quarter valued at approximately $29,000. Concord Wealth Partners grew its stake in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company's stock valued at $34,000 after acquiring an additional 363 shares during the period. Arrow Financial Corp purchased a new stake in Sanofi in the 2nd quarter worth $35,000. Finally, Fortitude Family Office LLC raised its position in Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock worth $43,000 after acquiring an additional 659 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, July 26th. Citigroup upgraded Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. Finally, StockNews.com cut Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $57.50.

Sanofi Stock Performance

NASDAQ SNY opened at $47.60 on Thursday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The firm has a market capitalization of $120.80 billion, a P/E ratio of 24.38, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. The stock's fifty day moving average is $54.05 and its two-hundred day moving average is $52.19. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the prior year, the firm posted $2.55 earnings per share. Sanofi's quarterly revenue was up 12.3% on a year-over-year basis. On average, research analysts anticipate that Sanofi will post 4.29 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.